anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Breast reduction surgery achieves symptomatic relief and improved quality of life for patients with excessive breast enlargement. Reduction mammoplasty has evolved over the last century with the introduction of multiple new pedicles and skin excision patterns utilizing the ample blood supply of the breasts. The superior pedicle is a relatively safe technique in small resections, while the superomedial pedicle, supplied by the internal mammary perforators, serves as a proper alternative in broader resections. We aim to introduce the dual-supply pedicle technique, taking advantage of the two efficient workhorse pedicles-the superior and superomedial. A retrospective study of 48 bilateral reduction mammoplasty patients operated over a 2-year period between 2017 and 2019 by a single surgeon (Y.W). Patient characteristics and postoperative outcome data were collected and evaluated. The novel surgical technique showed compatibility with different types of patients and breasts, forming excellent aesthetic outcomes. Complication rates were comparable or lower than previously published series. Major complications requiring revision surgery were encountered in 2 patients (2.08%) and minor complications in 11 patients (11.5%); 4 moderate surgical wound dehiscence, 6 minor surgical wound dehiscence and 1 fat necrosis. The Dual-Supply Pedicle Reduction Mammoplasty is a safe, reproducible technique, with a short learning curve, excellent aesthetical results, and an acceptable complication rate. Level of Evidence is Level III.
The invention relates to a medicine for treating tumors, which is prepared by utilizing solanum pseudo-capsicumvar diflorum (Vell.) Bitter as a raw material. The medicine for treating the tumors is prepared by utilizing entire solanum pseudo-capsicumvar diflorum (Vell.) Bitter, solanum pseudo-capsicumvar diflorum (Vell.) Bitter leaves, or solanum pseudo-capsicumvar diflorum (Vell.) Bitter fruit as a raw material, the solanum pseudo-capsicumvar diflorum (Vell.) Bitter fruit is preferably used as the raw material for preparing the medicine for treating the tumors, and the medicine has a better effect on treatment of the tumors.
This combines ART with a daily 30 minute practice of Kundalini Yoga (stretching, guided breathing, and meditation). Accessible by smart phone, tablet or computer.
PROBLEM TO BE SOLVED: To efficiently and selectively adsorb and remove C-type hepatitis virus in blood, by immobilizing a compound with adsorbability of C-type hepatitis virus to a water insoluble carrier. SOLUTION: This adsorbent for removing C-type hepatitis virus is made by immobilizing a compound with adsorbability to C-type hepatitis virus to a water insoluble carrier. The compound with adsorbability to C-type hepatitis virus is a compound with combining activity with immunoglobulin and/or an immunoglobulin complex. The compound with the combining activity is immunoglobulin combining protein or an anti-immunoglobulin antibody. The compound with adsorbability to C-type hepatitis virus more preferably is protein fragment, peptide, or their derivatives of part of immunoglobulin combined protein and/or anti-immunoglobulin antibody and containing a combining region to immunoglobulin and/or immunoglobulin complex. A porous form is preferable for the water insoluble carrier.
Patients should be alerted to the potential sedating effects caused by Ropinirole Extended-release Tablets, including somnolence and the possibility of falling asleep while engaged in activities of daily living. Since somnolence is a frequent adverse reaction with potentially serious consequences, patients should neither drive a car nor engage in other potentially dangerous activities until they have gained sufficient experience with Ropinirole Extended-release Tablets to gauge whether or not it affects their mental and/or motor performance adversely. Patients should be advised that if increased somnolence or episodes of falling asleep during activities of daily living (e.g., conversations, eating, driving a motor vehicle, etc.) are experienced at any time during treatment, they should not drive or participate in potentially dangerous activities until they have contacted their physician. 

Because of possible additive effects, caution should be advised when patients are taking other sedating medications, alcohol, or other CNS depressants (e.g., benzodiazepines, antipsychotics, antidepressants, etc.) in combination with Ropinirole Extended-release Tablets or when taking concomitant medications that increase plasma levels of ropinirole (e.g., ciprofloxacin) [see Warnings and Precautions (5.1)].
PURPOSE: Mild cognitive impairment (MCI) can be the prodromal phase of Alzheimer's disease (AD) where appropriate intervention might prevent or delay conversion to AD. Given this, there has been increasing interest in using magnetic resonance imaging (MRI) and neuropsychological testing to predict conversion from MCI to AD. Recent evidence suggests that the choroid plexus (ChP), neural substrates implicated in brain clearance, undergo volumetric changes in MCI and AD. Whether the ChP is involved in memory changes observed in MCI and can be used to predict conversion from MCI to AD has not been explored.
METHOD: The current study used data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database to investigate whether later progression from MCI to AD (progressive MCI [pMCI], n = 115) or stable MCI (sMCI, n = 338) was associated with memory scores using the Rey Auditory Verbal Learning Test (RAVLT) and ChP volumes as calculated from MRI. Classification analyses identifying pMCI or sMCI group membership were performed to compare the predictive ability of the RAVLT and ChP volumes.
FINDING: The results indicated a significant difference between pMCI and sMCI groups for right ChP volume, with the pMCI group showing significantly larger right ChP volume (p = .01, 95% confidence interval [-.116, -.015]). A significant linear relationship between the RAVLT scores and right ChP volume was found across all participants, but not for the two groups separately. Classification analyses showed that a combination of left ChP volume and auditory verbal learning scores resulted in the most accurate classification performance, with group membership accurately predicted for 72% of the testing data.
CONCLUSION: These results suggest that volumetric ChP changes appear to occur before the onset of AD and might provide value in predicting conversion from MCI to AD.
INTRODUCTION: Colorectal adenocarcinoma is rare in children and adolescents and tends to present with nonspecific signs and symptoms, leading to late diagnoses.
OBJECTIVES: Our aim was to describe the clinical presentation and progression in children and adolescents with colorectal adenocarcinoma treated at our hospital and detect possible predisposing conditions of this disease.
MATERIALS AND METHODS: Eight patients with colorectal adenocarcinoma were followed at the Hospital Posadas within the time frame of January 2000 and December 2021. We searched for diseases predisposing to this cancer.
RESULTS: The mean patient age was 16 years (between 11 and 17 years of age). Clinical presentation was abdominal pain in the 8 patients; 4 of them had pain in the right hypochondrium, 3 had abdominal tumor, 4 had rectal bleeding, and 3 had weight loss. Mean symptom duration was 9 weeks (range: 1-24 weeks). None of the patients showed predisposing illnesses. One patient presented with polyposis, with no cases in any other family member. Histology showed mucinous adenocarcinoma in all the patients, 4 of whom had the signet ring cell subtype. The primary tumor was located in the right colon in 6 patients. At diagnosis, staging according to the modified Dukes classification was: I: one patient; IIb: one patient; IIIb: one patient; IIIc: one patient; and IV: 4 patients. All patients except 2 received chemotherapy and one patient received radiotherapy. Overall survival at 3 years was 25%.
CONCLUSIONS: All patients presented with mucinous adenocarcinoma, no predisposing diseases were found, and the children with colorectal cancer had a very poor prognosis. Colorectal cancer diagnosis should be considered in children presenting with acute abdominal pain, abdominal tumor, or lower gastrointestinal bleeding, especially if there is weight loss.
This is a randomized, placebo-controlled crossover study. Participants with early Alzheimer's Disease (AD) will be tested in a double-blind crossover design with placebo, low-dose levetiracetam (LEV) 125 mg twice daily or high-dose LEV 500mg twice daily. These results will be contrasted with results from a demographically similar control group who will undergo baseline testing only, without any intervention, to establish a comparison norm for the AD group.

Each subject will undergo four screening and baseline visits consisting of a baseline neurological, medical, and cognitive evaluation. If amyloid status is unknown in AD patients, the participant will have an amyloid PET scan. Additional baseline measures include: a high density electroencephalogram (EEG); a 24 hour ambulatory EEG; functional magnetic resonance imaging (fMRI); neuropsychological testing; and transcranial magnetic stimulation with electromyogram (EMG) and EEG measures to assess cortical excitability. AD participants will be randomized to one of six possible groups that consists of a varying order of 3 treatment periods (LEV 125 mg, LEV 500 mg and placebo). The group assignments will be counterbalanced across subjects. Each treatment period will last for 4 weeks with a 4 week washout between treatments. All participants will be assessed prior to initiation of a treatment period (with the initial assessment occurring as part of the baseline assessment) and at the end of each treatment period. The following measures will be repeated as done at baseline at these time points: fMRI; neuropsychological testing; and TMS-EMG-EEG. AD participants will be enrolled for approximately 5 months.
The present invention relates to a process for preparing ganoderma tricterpinyl acid and ganoderma amylose from ganoderma. A dry ganoderma seed entity (with the water content of 5 to 8%) is crushed into a granular object or is cut into slice-shaped object. Then, raw materials are placed into a high pressure extraction tank. Subsequently, CO2 and a polarity agent are respectively injected into the extraction tank by a supercritical CO2 high pressure pump and a polarity agent high pressure pump. The extraction pressure of the high pressure pumps is from 25 to 50MPa, and the injection quantity of the polarity agent is from 10 to 20% by volume percentage. Temperature is from 35 to 80 DEG C, extraction time is from 2 to 4 hours, and thus, ganoderma tricterpinyl acid extract liquid is obtained. Water which is 8 to 16 times of the weight percentage of the extracted residual object is added into an extracted residual object to be heated at 80 to 100 DEG C, the extraction time is from 1 to 2 hours, and thus, ganoderma amylose extract liquid is obtained. In a product, the content of the ganoderma tricterpinyl acid reaches 60.2%(by high efficiency liquid phase chromatography detection), and the content of the ganoderma amylose reaches 36%(by ultraviolet spectrometry detection).
Systems and methods of determining an ergonomic assessment for a user are provided. For instance, sensor data can be received from one or more sensors implemented with an ergonomic assessment garment worn by a user. Corporeal data associated with at least one body segment of the user can be determined based at least in part on the sensor data. The corporeal data is associated with a bend angle associated with the at least one body segment. An ergonomic assessment associated with the user can be determined based at least in part on the corporeal data. The ergonomic assessment can include an indication of one or more ergonomic zones associated with the user, the one or more ergonomic zones being determined based at least in part on the bend angle associated with the at least one body segment.
Nasal Pollution/Anti-pollution Cleaning Spray & Rinse Nasal Pollution/Anti-pollution Cleaning Spray & Rinse consists of a new combination of ingredients in a nasal spray and lavage, that provides mechanical removal of nasal irritants and pollution debris. It also contains anti-oxidant and other ingredients to counteract the effects of pollution on the nasal and sinus mucosa. This may aid in repair of the membranes and ciliary flow. This may improve nasal function, help removal of pollution and other debris which in turn may improve lung mucosal function. It contains saline, antioxidants and others ingredients. It also contains ingredients that may help combat infection
The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes a diversity element which potentially binds to a target molecule with a dissociation constant of less than 300 μM and a linker element connected to the diversity element. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to said diversity element, and is capable of forming a reversible covalent bond or non-covalent interaction with a binding partner of the linker element. The monomers can be covalently or non-covalently linked together to form a therapeutic multimer or a precursor thereof. Also disclosed is a method of screening for therapeutic multimer precursors which bind to a target molecule associated with a condition and a method of screening for linker elements capable of binding to one another. The present invention additionally relates to a therapeutic multimer, which includes a plurality of covalently or non-covalently linked monomers, therapeutic monomers, and uses of such dimers and monomers.
Fluoride varnish painted on the teeth is the standard method dentists use to prevent tooth decay (cavities) in preschool children in the United States. Fluoride varnish is not FDA approved specifically for prevention of cavities, but dentists may legally use it for this purpose. We want to study how much fluoride appears in the urine after the painting procedure to improve our knowledge of how the varnish works and its safety. The fluoride varnish is being used for research purposes for this study by permission of FDA (IND #110869).

Premier Dental Product Company's Enamel Pro Varnish will be used. Up to six children aged 12-15 months will be enrolled in this study. We measured urinary fluoride for 5 hours after application of fluoride varnish to teeth. Baseline levels were measured on a separate day.
OBJECTIVE: Our objective was to evaluate the relationship between scalp-EEG and stereoelectroencephalography (SEEG) seizure-onset patterns (SOP) in patients with MRI-negative drug-resistant focal epilepsy.
METHODS: We analyzed retrospectively 41 patients without visible lesion on brain MRI who underwent video-EEG followed by SEEG. We defined five types of SOPs on scalp-EEG and eight types on SEEG. We examined how various clinical variables affected scalp-EEG SOPs.
RESULTS: The most prevalent scalp SOPs were rhythmic sinusoidal activity (56.8%), repetitive epileptiform discharges (22.7%), and paroxysmal fast activity (15.9%). The presence of paroxysmal fast activity on scalp-EEG was always seen without delay from clinical onset and correlated with the presence of low-voltage fast activity in SEEG (sensitivity = 22.6%, specificity = 100%). The main factor explaining the discrepancy between the scalp and SEEG SOPs was the delay between clinical and scalp-EEG onset. There was a correlation between the scalp and SEEG SOPs when the scalp onset was simultaneous with the clinical onset (p = 0.026). A significant delay between clinical and scalp discharge onset was observed in 25% of patients and featured always with a rhythmic sinusoidal activity on scalp, corresponding to similar morphology of the discharge on SEEG. The presence of repetitive epileptiform discharges on scalp was associated with an underlying focal cortical dysplasia (sensitivity = 30%, specificity = 90%). There was no significant association between the scalp SOP and the epileptogenic zone location (deep or superficial), or surgical outcome.
SIGNIFICANCE: In patients with MRI-negative focal epilepsy, scalp SOP could suggest the SEEG SOP and some etiology (focal cortical dysplasia) but has no correlation with surgical prognosis. Scalp SOP correlates with the SEEG SOP in cases of simultaneous EEG and clinical onset; otherwise, scalp SOP reflects the propagation of the SEEG discharge.
PLAIN LANGUAGE SUMMARY: We looked at the correspondence between the electrical activity recorded during the start of focal seizure using scalp and intracerebral electrodes in patients with no visible lesion on MRI. If there is a fast activity on scalp, it reflects similar activity inside the brain. We found a good correspondence between scalp and intracerebral electrical activity for cases without significant delay between clinical and scalp electrical onset (seen in 75% of the cases we studied). Visualizing repetitive epileptic activity on scalp could suggest a particular cause of the epilepsy: a subtype of brain malformation called focal cortical dysplasia.
A drug-resistant replication-defective influenza virus is constructed by means of using the characteristic of segmentation of the influenza virus genome in combination with a gene codon extension technique, and a new anti-influenza virus treatment method is established. According to the known genome sequence of the drug-resistant influenza virus strain, 12 drug-resistant influenza virus strains are obtained by means of a molecular cloning technique, and the drug resistance rate thereof against common anti-influenza drugs is evaluated. On the basis of the drug-resistant influenza virus strain, a PTC mutation is introduced to construct seven drug-resistant replication-defective influenza virus (DRRIV) strains; and a visual marker influenza virus for detecting the recombination rate of each segment of the influenza virus is also constructed. On the basis of the packaging efficiency of the seven DRRIV strains, the recombination rate of each segment and the therapeutic effect on the wild-type influenza virus, NA28TAG/H274Y with the best effect is screened out. The result indicates that NA28TAG/H274Y can recombine with the wild-type influenza virus and incorporate PTC into the recombinant progeny virus to inhibit virus proliferation, and has a broad-spectrum neutralization activity. The combined use of NA28TAG/H274Y and small molecule NA inhibitors (NAIs) further enhances the neutralization effect of NA28TAG/H274Y on the wild-type influenza virus. A mouse model indicates that NA28TAG/H274Y and oseltamivir produce a joint synergistic effect on the drug-resistant influenza virus.
The control group received neoadjuvant chemoradiotherapy and the regimen was as follows:Chemotherapy regimen: TP regimen: albumin paclitaxel + carboplatin, D1 administration, 2 cycles. Every 3 weeks, there was a dosing cycle (Q3W). Radiotherapy regimen: according to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week. Surgery was performed 6-8 weeks after completion of neoadjuvant therapy. If the patients without vital tumor cells in primary and lymph nodes after surgery, they only need regular follow-up visit. If the patients with non-pCR resected, those patients need to receive adjuvant immunotherapy. And if the patients with non-R0 resected, the regimen of those patients need to carefully decide based on multidisciplinary team discussed.
The present invention relates to a recombinant vector comprising a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) targeting trans-splicing ribozyme expression cassette for delivering a chimeric antigen receptor including (i) a trans-splicing ribozyme for targeting CTLA-4 and (ii) a polynucleotide for encoding a chimeric antigen receptor connected with a 3 exon of the ribozyme. Moreover, the present invention relates to a transformed cell in which the recombinant vector is introduced, a ribozyme expressed from the recombinant vector, a retrovirus for expressing the ribozyme, and a T cell treated by the retrovirus. Furthermore, the present invention relates to a pharmaceutical composition for preventing or treating cancer, wherein the pharmaceutical composition comprises the recombinant vector, the transformed cell, the ribozyme, the retrovirus, the T cell, or a combination thereof; and to a method for treating cancer, wherein the method comprises a step of administrating the recombinant vector, the transformed cell, the ribozyme, the retrovirus, the T cell, or a combination thereof into an entity requiring cancer treatment. The recombinant vector and the ribozyme expressed therefrom according to the present invention control CTLA-4 of a T cell, which has disturbed conventional anticancer treatment. At the same time, the recombinant vector and the ribozyme expressed therefrom make anticancer treatment possible. Accordingly, toxicity affecting normal cell is reduced through a gene cell therapy by which a more effective anticancer effect can be expected, so a treating effect and stability are improved. Thus, the recombinant vector and the ribozyme expressed therefrom can be widely utilized in the field of gene treatment in the future.
The present invention relates to the diagnosis and the treatment of reproduction-related disorders, in particular due to altered levels of GnrH, and also relates to contraception. The treatments based on hormone administration may have some limits. The inventors showed that miR200, miR155 and the respective Block-miRs may restore appropriate levels of GnrH. In particular, the present invention relates to the prevention or the treatment of a reproduction-related disorder due to a low expression of GnRH in an individual, comprising a step of administering a compound selected in a group comprising a miR200 and/or miR155 nucleic acid, a compound mimicking a miR200 and/or miR155 nucleic acid. Similarly, the invention also relates the prevention or the treatment of a reproduction-related disorder due to a high expression of GnRH, comprising a step of administering a compound selected in a group comprising a compound preventing the binding of a miR200 or a miR155 nucleic acid to a target nucleic acid. Particularly, the inventors have tested these compounds on mice.
Recently, organ preservation has gained importance for head and neck malignancies. The negative consequences of the therapies can be reduced without compromising the survival and the quality of life. Accordingly, transoral robotic surgery (TORS) is gaining ground internationally. We have been performing TORS procedures at the University of Pécs since January 2023. We operated on 27 patients until July 2024, including fifteen p16-positive tumors. Neck dissections were performed in 19 cases. The use of TORS is helpful in oropharyngeal cases, where inaccessible structures can be reached minimally invasively, compared to other transoral approaches. This is important for young patients with human papillomavirus-associated tumors, which have a better prognosis and longer life expectancy. TORS also has advantages over the previously used approaches for cancer of unknown primary (CUP). Compared to the standardly used FDG-PET/CT and "blindly" taken biopsies, TORS offers a higher detection rate of the primary tumor, by performing tonsillectomy and complete mucosectomy of the tongue base.
Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o. q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o. q.d. for 96 weeks. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o. q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o. q.d. for an additional 96 weeks. Eligible participants may continue to receive the Doravirine regimen in Study Extension 2 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first. Eligible participants may continue to receive the Doravirine regimen in Study Extension 3 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.